Ahuja Vineet, Bhatia Vikram, Dattagupta S, Raizada Akshay, Sharma Mahesh Prakash
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Dig Dis Sci. 2005 Apr;50(4):630-3. doi: 10.1007/s10620-005-2548-2.
In vitro activity of rifampicin has been shown against H. pylori. It has also been reported that the prevalence of H. pylori is low in patients with tuberculosis treated with rifampicin. Clinical trials are required to establish the efficacy of rifampicin as a salvage therapy for eradication of H. pylori. We aimed to evaluate the efficacy of rifampicin-based salvage therapy for eradication of H. pylori in patients with peptic ulcer disease. Twenty-eight patients with peptic ulcer disease who either had failed eradication of H. pylori or had a recurrence of H. pylori following successful eradication were included in the prospective study. The inclusion criteria included one or more failed attempts at eradication and presence of H. pylori infection as evidenced by positivity of at least two of three tests: rapid urease test (RUT), 14C urea breath test (UBT), and histology. The subjects were treated with a 10-day regimen consisting of rifampicin, 450 mg od, tetracycline, 1 g bd, and esomeprazole, 40 mg bd. Four weeks after completion of therapy, H. pylori status was assessed by RUT, 14C, UBT, and histology. Liver function tests were done before and at the end of therapy. The study subjects included 25 males and 3 females with a mean age of 33.7+/-8.92 years (range: 22-65 years). The median duration of symptoms was 42 months, with a range of 1-180 months. The median number of eradication attempts was two, with one prior attempt in 6 (21.4%), two attempts in 19 (67.9%), and three attempts in 3 (10.7%) patients. Successful H. pylori eradication as defined by concomitant negativity of RUT, UBT, and histology with special stains was achieved in 32.1% (9/28) of patients by intention-to-treat and 33.3% (9/27) of patients by per-protocol analysis. This pilot study suggests that rifampicin-based regimes have no role as salvage eradication therapy in refractory cases of H. pylori infection with peptic ulcer disease.
利福平对幽门螺杆菌已显示出体外活性。也有报道称,接受利福平治疗的结核病患者中幽门螺杆菌的感染率较低。需要进行临床试验来确定利福平作为根除幽门螺杆菌挽救疗法的疗效。我们旨在评估以利福平为基础的挽救疗法对消化性溃疡病患者根除幽门螺杆菌的疗效。本前瞻性研究纳入了28例幽门螺杆菌根除失败或成功根除后复发的消化性溃疡病患者。纳入标准包括一次或多次根除尝试失败,以及通过快速尿素酶试验(RUT)、¹⁴C尿素呼气试验(UBT)和组织学这三项检查中至少两项呈阳性证明存在幽门螺杆菌感染。受试者接受为期10天的治疗方案,包括利福平450毫克每日一次、四环素1克每日两次和埃索美拉唑40毫克每日两次。治疗结束四周后,通过RUT、¹⁴C-UBT和组织学评估幽门螺杆菌感染情况。在治疗前和治疗结束时进行肝功能检查。研究对象包括25名男性和3名女性,平均年龄为33.7±8.92岁(范围:22 - 65岁)。症状的中位持续时间为42个月,范围为1 - 180个月。根除尝试的中位次数为两次,其中6例(21.4%)曾进行过一次尝试,19例(67.9%)进行过两次尝试,3例(10.7%)进行过三次尝试。在意向性分析中,32.1%(9/28)的患者实现了幽门螺杆菌的成功根除,定义为RUT、UBT和组织学特殊染色均为阴性;按符合方案分析,33.3%(9/27)的患者实现了成功根除。这项初步研究表明,对于消化性溃疡病幽门螺杆菌感染难治性病例,以利福平为基础的治疗方案作为挽救性根除疗法并无作用。